Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease

IMPORTANCE: The proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab has been demonstrated to reduce the composite of myocardial infarction, stroke, or cardiovascular death in patients with established atherosclerotic cardiovascular disease. To our knowledge, long-term cost-effectivene...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Cardiol
Main Authors: Fonarow, Gregg C., Keech, Anthony C., Pedersen, Terje R., Giugliano, Robert P., Sever, Peter S., Lindgren, Peter, van Hout, Ben, Villa, Guillermo, Qian, Yi, Somaratne, Ransi, Sabatine, Marc S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2017
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5710446/
https://ncbi.nlm.nih.gov/pubmed/28832867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2017.2762
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados